BCLI Logo

Brainstorm Cell Therapeutics Inc. (BCLI) 

NASDAQ
Market Cap
$8.5M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
173 of 776
Rank in Industry
104 of 433

Largest Insider Buys in Sector

BCLI Stock Price History Chart

BCLI Stock Performance

About Brainstorm Cell Therapeutics Inc.

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing …

Insider Activity of Brainstorm Cell Therapeutics Inc.

Over the last 12 months, insiders at Brainstorm Cell Therapeutics Inc. have bought $283,114 and sold $22,069 worth of Brainstorm Cell Therapeutics Inc. stock.

On average, over the past 5 years, insiders at Brainstorm Cell Therapeutics Inc. have bought $348,395 and sold $491,363 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Lebovits Chaim (President & CEO) — $283,114.

The last purchase of 1,836 shares for transaction amount of $6,292 was made by Lebovits Chaim (President & CEO) on 2024‑10‑01.

List of Insider Buy and Sell Transactions, Brainstorm Cell Therapeutics Inc.

2024-10-01PurchasePresident & CEO
1,836
0.031%
$3.43$6,292-33.85%
2024-09-30PurchasePresident & CEO
22,000
0.0247%
$0.23$5,016-37.25%
2024-07-19SaleChief Medical Officer
63,000
0.0801%
$0.35$22,069-21.77%
2024-05-28PurchasePresident & CEO
15,000
0.0215%
$0.52$7,775-37.81%
2024-05-22PurchasePresident & CEO
25,000
0.0399%
$0.64$16,000-43.36%
2024-05-21PurchasePresident & CEO
25,000
0.0333%
$0.58$14,475-47.26%
2024-05-13PurchasePresident & CEO
10,000
0.0131%
$0.49$4,900-38.63%
2024-05-11PurchasePresident & CEO
10,000
0.015%
$0.47$4,665-20.07%
2024-05-10PurchasePresident & CEO
20,000
0.0298%
$0.47$9,300-26.17%
2024-05-07PurchasePresident & CEO
66,300
0.0971%
$0.37$24,816-7.97%
2024-05-06PurchasePresident & CEO
135,000
0.1982%
$0.38$50,666-9.45%
2024-04-19PurchasePresident & CEO
15,000
0.0214%
$0.52$7,799-35.28%
2024-04-18PurchasePresident & CEO
115,072
0.172%
$0.53$60,470-32.68%
2024-04-17PurchasePresident & CEO
130,000
0.1919%
$0.55$70,941-35.51%
2023-09-01PurchaseCo-Chief Executive Officer
11,500
0.0277%
$1.77$20,402-78.57%
2020-07-16Sale
7,823
0.0252%
$13.47$105,351-62.10%
2020-07-16PurchaseEVP and COO
5,000
0.0155%
$12.95$64,740-62.10%
2020-07-15Sale
18,430
0.06%
$13.12$241,715-60.36%
2020-07-15Purchasedirector
46,779
0.1507%
$12.99$607,659-60.36%
2020-07-13Sale
40,000
0.1354%
$13.52$540,952-59.56%

Insider Historical Profitability

<0.0001%
Lebovits ChaimPresident & CEO
80960
1.5231%
$1.60130
ACCBT Corp.10 percent owner
7075000
133.0986%
$1.6050
Abbhi Sankeshdirector
2164530
40.7203%
$1.6010
Lindborg StacyCo-Chief Executive Officer
181500
3.4145%
$1.6010<0.0001%
ARBEL IRITdirector
155833
2.9316%
$1.6011<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
The Vanguard Group$791,140.001.761.4M-1.57%-$12,602.40<0.0001
BlackRock$276,315.000.62489,313+4.92%+$12,964.38<0.0001
Geode Capital Management$201,711.000.45357,0410%+$0<0.0001
Liberty Wealth Management Llc$192,000.000.43340,1500%+$00.05
Weaver Consulting Group$112,577.000.25199,3560%+$00.05
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.